Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

JACC Basic Transl Sci. 2021 Jan 6;6(1):12-21. doi: 10.1016/j.jacbts.2020.10.006. eCollection 2021 Jan.


We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation.

Keywords: AIx, augmentation index; AP, augmentation pressure; CITP, N-terminal telopeptide of type I collagen; Gal-3, galectin-3; HF, heart failure; LV, left ventricular; MCP, modified citrus pectin; MMP, matrix metalloproteinase; PICP, C-terminal propeptide of type I procollagen; PIIINP, N-terminal propeptide of type III procollagen; PWV, pulsed wave velocity; cardiac fibrosis; eGFR, estimated glomerular filtration rate; galectin-3; heart failure.